Bruker (BRKR) Tops Q2 EPS by 1c; raises guidance

Bruker (NASDAQ: BRKR) reported Q2 EPS of $0.50, $0.01 better than the analyst estimate of $0.49. Revenue for the quarter came in at $681.9 million versus the consensus estimate of $647.82 million.

GUIDANCE:

Bruker sees FY2023 EPS of $2.55-$2.60, versus the consensus of $2.58. Bruker sees FY2023 revenue of $2.85-2.9 billion, versus the consensus of $2.866 billion.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Astrana Health (ASTH) Mentioned as short at Glass House